-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2024-513633-20-00
4
2022-10-28
recurrent prostate cancer
-
2023-509429-37-00
5
2022-10-03
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-510019-20-00
5
2022-07-13
Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis
-
2022-500014-26-00
5
2022-06-24
Locally-Advanced unresectable or Metastatic breast cancer (MBC)
-
2023-506854-19-00
1
2022-05-19
Solid Tumors
-
2023-507131-38-00
5
2022-05-16
Neovascular Age-Related Macular Degeneration (nAMD)
-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2024-511209-49-00
6
2022-04-26
Patients with hormone receptor positive HER2 negative locally advanced
-
2023-509372-41-00
5
2022-01-30
Multiple Sclerosis
-
2024-511407-42-00
4
2022-01-10
Advanced Systemic Mastocytosis
-
2024-511535-97-00
10
2021-12-16
sickle cell disease (SCD)
-
2023-504320-25-00
4
2021-11-25
Active Systemic Lupus Erythematosus
-
2023-506450-20-00
5
2021-11-05
Rheumatoid Arthritis
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2023-503441-55-00
4
2021-10-14
Relapsed/Refractory Multiple Myeloma
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2024-513091-17-00
5
2021-09-29
Progressive myopia
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-510307-22-00
1
2021-09-24
Advanced head and neck cancer
-
2023-508690-92-00
11
2021-09-20
IgA Nephropathy
-
2023-506368-14-00
5
2021-09-07
Systemic lupus erythematosus (SLE)
-
2023-505850-16-00
5
2021-08-05
Multiple Myeloma
-
2024-511321-54-00
5
2021-08-04
intermediate-high-risk acute pulmonary embolism